Form 4: Intellia Therapeutics Director William Chase Reports Significant Equity Grants

Intellia Therapeutics, Inc. Director William J. Chase reported the acquisition of 8,000 restricted stock units and 11,450 stock options on June 11, 2025, increasing his direct beneficial ownership.

Summary

• Director William J. Chase of Intellia Therapeutics, Inc. acquired 8,000 shares of common stock through a grant of restricted stock units (RSUs) on June 11, 2025, at a price of $0 per share.
• Following this transaction, Mr. Chase directly beneficially owns 34,693 shares of common stock.
• Additionally, Mr. Chase was granted 11,450 stock options on June 11, 2025, with an exercise price of $8.37 per share and an expiration date of June 10, 2035.
• These stock options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date.
• The filing was signed by Edward Dulac, attorney-in-fact, on June 13, 2025, under a Limited Power of Attorney executed by William Chase on October 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a director acquiring additional equity through grants, which aligns their interests with shareholders and indicates confidence in the company's future. This is a standard compensation event, but the increase in beneficial ownership is a positive signal.

Positives

• Director William J. Chase received a grant of 8,000 restricted stock units, aligning his interests with shareholders.
• Director William J. Chase was granted 11,450 stock options, providing an incentive for long-term performance and value creation.
• The acquisition of equity by a director indicates continued commitment to the company.

Future Outlook

The vesting schedule for the granted stock options indicates a future milestone tied to either the first anniversary of the grant date or the next annual meeting of stockholders, suggesting a forward-looking incentive structure for the director.

Industry Context

This filing is typical for executive and director compensation in the biotechnology and pharmaceutical industry, where equity grants like restricted stock units and stock options are common tools to align management incentives with long-term shareholder value and retain key talent. Such grants are standard practice for publicly traded companies like Intellia Therapeutics, a gene-editing company, to incentivize leadership in a high-growth, research-intensive sector.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to equity grants.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The stock options granted on June 11, 2025, will vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date.

Key Dates

Recommendation

Keywords

Intellia Therapeutics, NTLA, SEC Form 4, Insider Transaction, Stock Grant, Restricted Stock Units, Stock Options, Director Compensation, Equity Compensation, William Chase